Biotech · Private company · Van Nuys, CA, US
Trace-Ability, Inc.
Track this companyFree. Adds Trace-Ability, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards6
- Improving availability of ImmunoPET via automation of radio-synthesis and quality control of antibody-based HIV imaging PET tracers on a single platform.Fiscal year 2026 · $1MNIH RePORTER 5R44AI162202-04 · fetched Nov 12, 2026
- Enabling nationwide AD PET imaging to support most efficient clinical trials by adoption of radically simplified and standardized quality control in commercial production of AD PET tracers.Fiscal year 2025 · $1.5MNIH RePORTER 5R44AG071409-04 · fetched Nov 12, 2026
- Improving availability of ImmunoPET via automation of radio-synthesis and quality control of antibody-based HIV imaging PET tracers on a single platform.Fiscal year 2025 · $1MNIH RePORTER 5R44AI162202-03 · fetched Nov 12, 2026
- Enabling nationwide AD PET imaging to support most efficient clinical trials by adoption of radically simplified and standardized quality control in commercial production of AD PET tracers.Fiscal year 2024 · $1.5MNIH RePORTER 2R44AG071409-03 · fetched Nov 12, 2026
- Establishing industrial production of components that enable expanding accessibility of PET imaging to cancer patient population.Fiscal year 2024 · $93.8KNIH RePORTER 5SB1CA192499-05 · fetched Nov 12, 2026
- Improving availability of ImmunoPET via automation of radio-synthesis and quality control of antibody-based HIV imaging PET tracers on a single platform.Fiscal year 2024 · $1MNIH RePORTER 9R44AI162202-02A1 · fetched Nov 12, 2026